SCHEMBL33528006

SCHEMBL33528006

NCc1n[nH]c2cccc(F)c12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR2A P28223 2/20 0.44
▸ KDR P35968 6/20 0.41
▸ ROCK1 Q13464 4/20 0.41
▸ LCK P06239 3/20 0.41
▸ CSF1R P07333 3/20 0.41
▸ FGFR1 P11362 3/20 0.41
▸ CDK5 Q00535 3/20 0.41
▸ CLK4 Q9HAZ1 3/20 0.41
▸ MAP2K1 Q02750 2/20 0.41
▸ PRKACA P17612 2/20 0.41
▸ DAPK3 O43293 2/20 0.41
▸ PRKD3 O94806 2/20 0.41
▸ MAP4K4 O95819 2/20 0.41
▸ NTRK1 P04629 2/20 0.41
▸ RET P07949 2/20 0.41
▸ MET P08581 2/20 0.41
▸ FLT1 P17948 2/20 0.41
▸ MAPK8 P45983 2/20 0.41
▸ MAPK9 P45984 2/20 0.41
▸ CSNK1A1 P48729 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10271520 0.82 FFAR1 (0.40) HTR2AKDRROCK1LCKCSF1R
SCHEMBL19724600 0.78 FFAR1 (0.37) HTR2AKDRROCK1LCKCSF1R
SCHEMBL2328937 0.78 PARP1 (0.47) KDRROCK1LCKCSF1RFGFR1
SCHEMBL3944570 0.77 KDR (0.38) HTR2AKDRROCK1LCKCSF1R
SCHEMBL31411355 0.76 HTR2A (0.55) HTR2AKDRDYRK1AFFAR1GPR84
SCHEMBL30248298 0.76 GAA (0.61) KDRROCK1LCKCSF1RFGFR1
SCHEMBL185907 0.76 GAA (0.61) KDRROCK1LCKCSF1RFGFR1
SCHEMBL3443437 0.72 CYP1A2 (0.43) HTR2AKDRROCK1LCKCSF1R
SCHEMBL1573886 0.72 GAA (0.43) HTR2AKDRROCK1LCKCSF1R
SCHEMBL11904474 0.72 KDR (0.40) HTR2AKDRROCK1LCKCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260091026-A1 METHODS OF TREATING INFLAMMATORY DISEASES INTERLINE THERAPEUTICS INC (US) 2026-04-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260091026-A1 METHODS OF TREATING INFLAMMATORY DISEASES NR3C1, NR3C2, CCR1 HTR2A 899/4885KDR 2977/4885ROCK1 2753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback